title: Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody.
abstract: We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.
authors.affiliation: The Third Department of Medicine, Shinshu University School of Medicine, Matsumoto, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
authors.forename: Takahisa
authors.initials: T
authors.lastname: Gono
authors.forename: Masayuki
authors.initials: M
authors.lastname: Matsuda
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimojima
authors.forename: Wataru
authors.initials: W
authors.lastname: Ishii
authors.forename: Kanji
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Morita
authors.forename: Takao
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Susuki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yuki
authors.forename: Shu-ichi
authors.initials: S
authors.lastname: Ikeda
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005915:Globosides / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000627:therapeutic use*; D008297:Male; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000503:physiopathology; D011930:Reaction Time / Q000187:drug effects / Q000528:radiation effects; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D005915:Globosides; D007075:Immunoglobulin M; C051917:sulfate-3-glucuronyl paragloboside; D000069283:Rituximab